Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors

NCT03950570 is registered in ClinicalTrials.gov with Orinove, Inc. as lead sponsor.

NCT NCT03950570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03950570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, Dose-Escalation and Expansion Study of Oral ORIN1001 with and Without Chemotherapy in the Treatment of Subjects with Solid Tumors
Lead sponsor
Orinove, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 25, 2019
Completion date
January 30, 2023
Enrollment
58 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic breast cancer